AZD6234
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Diabetes, Type IIEndocrinologyHealthy ParticipantsHepatic ImpairmentInvestigating obesity or overweight condition correlated to many co-morbiditiesObesityObesity or OverweightObesity or Overweight
Weight-Related Comorbidity
with/without Diabetes Mellitus
Phase 1
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
CompletedNCT05511025
Start: 2022-09-20End: 2023-12-19Updated: 2023-12-26
A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living with Obesity and Overweight with or without Type 2 Diabetes Mellitus
Active, not recruitingCTIS2023-504215-32-00
Start: 2023-09-28Target: 101Updated: 2025-10-15
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
CompletedNCT06132841
Start: 2023-11-13End: 2026-03-07Updated: 2026-04-03
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
CompletedNCT06845813
Start: 2025-02-24End: 2025-09-30Updated: 2025-11-03
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
Active, not recruitingNCT07013643
Start: 2025-06-04End: 2027-07-09Updated: 2026-10-13
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
RecruitingNCT07546760
Start: 2026-03-20End: 2027-02-04Target: 28Updated: 2026-10-22
Phase 2
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
CompletedNCT06595238
Start: 2024-10-01End: 2025-12-03Updated: 2026-10-02
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or
Overweight with Comorbidity
Active, not recruitingCTIS2024-516176-15-00
Start: 2025-02-24Target: 40Updated: 2025-12-22
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
CompletedNCT06851858
Start: 2025-03-12End: 2026-05-26Updated: 2026-09-24
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
CompletedNCT06862791
Start: 2025-02-18End: 2026-05-11Updated: 2026-06-03
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
Active, not recruitingNCT07017179
Start: 2025-05-20End: 2026-10-23Updated: 2026-09-29
Phase 3
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus
Not yet recruitingCTIS2025-523295-23-00
Target: 35Updated: 2026-09-21
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight
Not yet recruitingCTIS2025-524616-11-00
Target: 195Updated: 2026-10-06
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus
Not yet recruitingCTIS2025-523379-41-00
Target: 627Updated: 2026-10-09